Durable vision outcomes and extended Tx interval with aflibercept 8 mg in nAMD and DME: Insights for clinical practice
23 Apr 2025
byProf. Michael Stewart, Mayo Clinic, Jacksonville, Florida, US
Anti-vascular endothelial growth factor (anti-VEGF) agents are considered the standard of care (SoC) for neovascular agerelated macular degeneration (nAMD) and diabetic macular oedema (DME). However, the need for frequent intravitreal (IVT) injections leads to a substantial treatment burden. In an interview with MIMS Doctor, Professor Michael Stewart of the Mayo Clinic in Jacksonville, Florida, US, discussed how the highdose formulation of the anti-VEGF agent, aflibercept 8 mg, may address challenges associated with nAMD and DME management based on results of the pivotal PULSAR and PHOTON trials as well as his patients’ early experience.
